Special Article

International Diabetes Federation guideline for management of postmeal glucose: a review of recommendations

A. Ceriello and S. Colagiuri*

Clinical Science Research Institute, Warwick Medical School, Coventry, UK and *Institute of Obesity, Nutrition, and Exercise, University of Sydney, Sydney, NSW, Australia

Accepted 25 July 2008

Abstract

Diabetes is a significant and growing concern, with over 246 million people around the world living with the disease and another 308 million with impaired glucose tolerance. Depending on the resources of different nations, intervention has generally focused on optimizing overall glycaemic control as assessed by glycated haemoglobin (HbA₁c) and fasting plasma glucose (FPG) values. Nevertheless, increasing evidence supports the importance of controlling all three members of the glucose triad, namely HbA₁c, FPG and postmeal glucose (PMG) in order to improve outcome in diabetes. As part of its global mission to promote diabetes care and prevention and to find a cure, the International Diabetes Federation (IDF) recently developed a guideline that reviews evidence to date on PMG and the development of diabetic complications. Based on an extensive database search of the literature, and guided by a Steering and Development Committee including experts from around the world, the IDF Guideline for Management of Postmeal Glucose offers recommendations for appropriate clinical management of PMG. These recommendations are intended to help clinicians and organizations in developing strategies for effective management of PMG in individuals with Type 1 and Type 2 diabetes. The following review highlights the recommendations of the guideline, the supporting evidence provided and the major conclusions drawn. The full guideline is available for download at www.idf.org.

Diabet. Med. 25, 1151–1156 (2008)

Keywords diabetes, guideline, macrovascular, postmeal glucose, self-monitoring of blood glucose

Abbreviations CIMT, carotid intima-media thickness; FPG, fasting plasma glucose; HbA₁c, glycated haemoglobin; IDF, International Diabetes Federation; IGT, impaired glucose tolerance; PMG, postmeal glucose; SMBG, self-monitoring of blood glucose

Introduction

Diabetes has no geographical boundaries and the disease, once ascribed to more affluent countries, is now known to profoundly affect developing nations [1]. More than 246 million people around the world are now living with diabetes and 308 million people are estimated to have impaired glucose tolerance (IGT) [1]. These alarming figures translate to an estimated 3.8 million people succumbing to the disease in the past year [1]. As a global issue, diabetes outcome is closely tied to the management strategies and resources available in the various regions of the world. However, even within the limitations of healthcare resources in certain nations, there is a need to optimize diabetes management to minimize related morbidity and mortality. Among the many methods recognized for improving outcome in diabetes, such as lifestyle modification and control of related risk factors, the importance of tailoring therapies to achieve specific glycaemic targets is increasingly apparent. Traditionally, intervention has largely focused on...
Glycated haemoglobin (HbA1c) and fasting plasma glucose (FPG) values (2). However, studies have highlighted the importance of targeting postmeal hyperglycaemia and demonstrate a strong relationship between elevated postmeal glucose (PMG) and the risk of complications (3–7).

As part of its global mission to promote diabetes care and prevention and to find a cure, the International Diabetes Federation (IDF) has developed a guideline that reviews the relationship between PMG and the development of diabetes complications, as well as recommendations for the appropriate management of PMG. Below is an overview of the guideline’s major conclusions and recommendations for management of postmeal glycaemia.

**Origin of guideline**

The postmeal guideline was developed under the direction of the IDF, through consultation of a Steering Committee (four members) and Development Committee (14 members). These committees were composed of individuals from around the world experienced at guideline development and healthcare delivery and living with diabetes (8). A series of four key questions served as the basis for an extensive, systematic search of the literature published over the past 20 years. Question 1: Is postprandial hyperglycaemia harmful? Question 2: Is treatment of postmeal hyperglycaemia beneficial? Question 3: Which therapies are effective in controlling postmeal plasma glucose? Question 4: What are the targets for postmeal glycaemic control and how should they be assessed? Relevant reports were obtained through a computerized search of the literature using PubMed and other search engines; scanning of incoming journals in the medical library and review of references in pertinent review articles, major textbooks and syllabi from national and international meetings on the subjects of diabetes, using relevant title and text words (e.g. postprandial, postmeal, hyperglycaemia, mealtime, self-monitoring, oxidative stress, inflammation) as search criteria. The committee reviewed over 1600 studies and numerous key reports before making recommendations based on the strength of the evidence. The draft guideline, which extended to management of PMG, was distributed for wider committee review by IDF member associations, global and regional IDF elected representatives, interested professionals, industry and others on IDF contact lists.

**Rationale for postmeal glucose control**

In people with normal glucose tolerance, plasma glucose generally rises no higher than 7.8 mmol/l (140 mg/dl) 2 h after the ingestion of food. Development of postmeal hyperglycaemia coincides with a loss of first-phase insulin secretion, a decrease in insulin sensitivity and an inability to adequately suppress hepatic glucose production (10–12). As frank diabetes develops (11), PMG excursions continue to worsen (13). The contribution of postmeal plasma glucose to HbA1c is proportionally greatest with HbA1c values of 6.5%, while nocturnal FPG is at a near-normal level. As HbA1c rises above 8%, the relative contribution of postmeal hyperglycaemia to overall glycaemic control diminishes, while the contribution of FPG predominates (13). These results explain previous findings that, while the contribution of postmeal plasma glucose to overall glycaemia is ~70% at HbA1c values < 7.3%, the postmeal contribution is ~40% with HbA1c values above 9.3% (14). Such findings form the basis for a glucose triad model of diabetes management, in which all three glycaemic parameters of HbA1c, PMG and FPG interrelate, and are essential targets for intervention in attempts to optimize overall glycaemic control (Fig. 1).

Postmeal or post-challenge hyperglycaemia is common in the diabetes population and is commonly found even in individuals considered to have adequate overall metabolic or glycaemic control. A cross-sectional study in the USA involving 218 individuals with Type 2 diabetes identified post-challenge glucose values ≥ 11.1 mmol/l (200 mg/dl) in nearly 74% of individuals overall and in 39% of those with HbA1c values < 7.0% (15). Individuals with Type 1 diabetes on ‘intensive’ insulin therapy are also typically subject to these glycaemic excursions, with 72-h continuous monitoring recording postmeal elevations above 7.8 mmol/l (140 mg/dl) in 77% of this patient population (16).

The closer the achieved HbA1c is to the normal range, the lower the risk of complications (17,18). Given that PMG is a major contribution to overall glycaemia across a range of HbA1c values (14), targeting postmeal hyperglycaemia may help reduce risk of complications. The evidence and recommendations for the management of PMG are reviewed.

**Question 1: Is postprandial hyperglycaemia harmful?**

Epidemiological studies have identified postmeal and post-challenge hyperglycaemia as independent risk factors for...
macrovascular disease in individuals with IGT and Type 2 diabetes [4,7,19–22]. Findings from two large-scale studies, the European ‘DECODE’ and the Asian ‘DECODA’ study, demonstrated 2-h plasma glucose to be a strong predictor of cardiovascular disease and all-cause mortality [20,21] and a better indicator than fasting glucose [21]. In addition, a meta-analysis of 38 prospective studies confirmed that, while cardiovascular risk increases linearly within a wide range of 2-h plasma glucose values, a threshold effect is detected for FPG values up to ~5.6 mmol/l (100 mg/dl) [4]. Postmeal hyperglycaemia more reliably predicted incidence of cardiovascular events in individuals with Type 2 diabetes than elevations in FPG, with cardiovascular risk greater in women than men when comparing the top vs. bottom tertiles of post-lunch plasma glucose values [19].

Along with population studies demonstrating an association between postmeal hyperglycaemia and macrovascular risk, surrogate markers of cardiovascular disease also appear to depend on PMG elevations. Even mild-to-moderate postmeal hyperglycaemia in individuals without diabetes was demonstrated to be an independent risk factor for development of carotid intima-media thickness (CIMT), a marker of atherosclerosis [7]. In addition, a causal association was found between postmeal hyperglycaemia and oxidative stress, inflammation and endothelial dysfunction [23,24] and adhesion molecules [25]. Significant reductions in myocardial blood flow and blood volume are observed following ingestion of a mixed meal in individuals with Type 2 diabetes, while such myocardial perfusion deficits are not found during the postmeal state in individuals without diabetes [26].

A number of other diabetes-related conditions are also associated with postmeal and post-challenge hyperglycaemia, including independent correlation with diabetic retinopathy and neuropathy, as well as an association with diabetic nephropathy [3], increased cancer risk [27] and cognitive dysfunction in elderly individuals with Type 2 diabetes [28].

**Recommendation**

- Postmeal hyperglycaemia is harmful and should be addressed.

**Question 2: Is treatment of postmeal hyperglycaemia beneficial?**

Although randomized controlled trials have not yet established whether controlling postmeal glycaemia will in itself reduce macrovascular or microvascular risk, evidence suggests that therapies ‘preferentially’ targeting postmeal hyperglycaemia appear to be beneficial [5,29,30]. Treatment with acarbose, an α-glucosidase inhibitor that delays carbohydrates absorption following meals, significantly reduced postmeal hyperglycaemia, along with risk of myocardial infarction and other cardiovascular events in individuals with Type 2 diabetes [5] and IGT [30]. A positive effect is also observed on CIMT in individuals with Type 2 diabetes with the use of repaglinide, a rapid-acting insulin secretagogue that preferentially targets PMG; after a 1-year study period, regression of CIMT (i.e. decrease in CIMT of > 0.02 mm) was observed in 52% of individuals receiving repaglinide, compared with only 18% of those treated with glibenclamide (glyburide) [29]. Similar findings are observed in individuals with IGT, demonstrating that acarbose therapy reduces CIMT progression compared with placebo control [31]. Rapid-acting insulin analogues also appear to have a positive effect on surrogate markers of cardiovascular disease, including nitrotyrosine, endothelial function and methylglyoxal (MG) and 3-deoxyglucosone (3-DG) [32–34], with acarbose treatment also showing some similar effects on these markers [35].

Along with evidence for a reduction in macrovascular risk with treatments that preferentially target PMG in individuals with Type 2 diabetes [5,29,30], findings from recent interventional studies demonstrate that targeting postmeal hyperglycaemia helps optimize HbA1c [6,36]. Individuals with Type 2 diabetes achieving a target HbA1c ≤ 7.0% had significantly lower PMG values after the end of a 3-month intensified diabetes management programme compared with those who did not [6]. Fasting levels were not significantly different between the two groups, suggesting that, although control of FPG alone was necessary, it was not sufficient for achieving the HbA1c target. In addition, severe hypoglycaemia was not associated with targeting postmeal hyperglycaemia.

**Recommendation**

- Implement treatment strategies to lower postmeal plasma glucose in people with postmeal hyperglycaemia.

**Question 3: Which therapies are effective in controlling postmeal plasma glucose?**

Guidelines from various professional diabetes organizations continue to encourage physical activity, nutritional intervention and weight control as essential components of a comprehensive programme for diabetes management [37–39]. Nevertheless, the precise composition of the ‘optimal’ diet is still debated, although reducing glycaemic load (GL) has emerged as a favourable option [40,41]. Glycaemic load is an estimate of the glycaemic effects of a diet, accounting for both the type of carbohydrate consumed [i.e. according to the glycaemic index (GI)] and the amount [40]. With glycaemic load and glycaemic index reliably predicting the glycaemic response following a mixed meal [40,41], nutritional planning that incorporates these measures may not only reduce PMG excursions but is also found to modestly lower HbA1c [42] and possibly reduce cardiovascular risk [43].

A number of therapeutic agents that preferentially lower postmeal plasma glucose are currently available. These therapies include α-glucosidase inhibitors, glinides (rapid-acting insulin secretagogues), rapid-acting insulin, biphasic (premixed) insulins and human regular insulin. In addition, newer classes of therapies have emerged that are also associated with a reduction in PMG excursions and improvement in
Therapeutic agents that preferentially lower postmeal plasma glucose and their mechanisms of action

**Table 1** Therapeutic agents that preferentially lower postmeal plasma glucose and their mechanisms of action

| Therapeutic class       | Physiological mechanism of action                                                                                                                                 |
|-------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Alpha-glucosidase inhibitors | Delays carbohydrate absorption from the gastrointestinal tract                                                                                                          |
| Amylin analogues         | Acts as a replacement for naturally occurring amylin, a hormone secreted by pancreatic B-cells along with insulin, that decreases glucagon release, slows gastric emptying and decreases food intake |
| DPP-4 inhibitors         | Inhibits DPP-4 enzyme that degrades GLP-1                                                                                                                           |
| GLP-1 derivatives        | Acts as a replacement for GLP-1, an incretin hormone secreted by the gut that stimulates insulin secretion, reduces glucagon secretion and delays gastric emptying rate |
| Rapid-acting insulins    | Developed to mimic physiological insulin response to meals with rapid onset and peak activity and short duration of action                                             |
| DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1. |                                                                                                                                                                      |

HbA1c: These agents include amylin analogues, glucagon-like peptide-1 (GLP-1) derivatives and dipeptidyl peptidase-4 (DPP-4) inhibitors [44,45] (Table 1).

**Recommendation**

- A variety of both non-pharmacologic and pharmacologic therapies should be considered to target postmeal plasma glucose.

**Question 4: What are the targets for postmeal glycaemic control and how should they be assessed?**

A 2-h postmeal goal of < 7.8 mmol/l (< 140 mg/dl) is recommended, in line with targets published in guidelines from other associations [8,39,46]. Such guidelines define normal glucose tolerance (NGT) as post-challenge values of ≤ 7.8 mmol/l 2 h after ingestion of a 75-g glucose load [1,37], corresponding to postmeal values of healthy individuals after meals [47]. The 2-h time frame for testing is also in agreement with published guidelines and in addition reflects the 2- to 3-h return of postmeal hyperglycaemia to basal levels in individuals with normal glucose tolerance [39,46].

The guideline encourages performing glucose monitoring as frequently as needed in order to guide therapy to achieve PMG targets. In particular, the guideline suggests considering self-monitoring of blood glucose (SMBG), as it is the only way to directly assess PMG. However, some degree of controversy surrounds SMBG use, particularly with respect to the frequency of monitoring in non-insulin requiring diabetes [48]. Nevertheless, most professional diabetes organizations continue to advocate its use [37,39,46], generally recommending that self-monitoring is performed at least three times daily in individuals treated with insulin and according to treatment regimen and level of glycaemic control in non-insulin dependent diabetes [37,38].

What is more, the use of structured SMBG appears to result in a significant reduction in HbA1c, even in individuals with non-insulin requiring diabetes [49]. These findings support the implementation of SMBG as part of a structured programme that may involve the training of clinicians and patients to accurately interpret results and adjust therapy accordingly in a timely manner.

**Glycaemic goals for clinical management of diabetes**

- HbA1c < 6.5%
- Premeal (fasting) < 5.5 mmol/l (< 100 mg/dl)
- Two hours postmeal < 7.8 mmol/l (< 140 mg/dl)

Note: Lower glucose parameters to as near normal as safely possible. Glycaemic targets should be individualized. These goals are not appropriate for children and pregnant women.

**Recommendations**

- Two-hour postmeal plasma glucose should not exceed 7.8 mmol/l (140 mg/dl) as long as hypoglycaemia is avoided.
- Self-monitoring of blood glucose should be considered because it is currently the most practical method for monitoring postmeal glycaemia.
- Efficacy of treatment regimens should be monitored as frequently as needed to guide therapy towards achieving postmeal plasma glucose target.

**Relevance of guideline and implications**

The importance of managing PMG to improve overall glycaemic control in diabetes is now fairly widely recognized in guidelines from professional associations [2,37–39,46]. As the research base continues to expand, the answers to other relevant questions are eagerly anticipated, such as whether there is a causal association between PMG and macrovascular complications and the role of SMBG in individuals who are not on insulin therapy. Until that time, logic and clinical judgment persist when interpreting the evidence presented in the guideline and deciding on an optimal management plan. Management strategies should depend on a practical evaluation of how best to integrate the recommendations into modern practice, with consideration to locally available therapies and resources.

**Conclusions**

Postmeal hyperglycaemia occurs early in the development of diabetes, progressively worsens with deteriorating HbA1c, and is often inadequately controlled. In addition, elevations in
PMG are strongly associated with a number of serious complications of diabetes, both through a direct contribution to HbA1c as well as an independent association with various diabetes-related complications. Based on evidence to date, the guideline recommends implementing a comprehensive management programme that targets both postmeal and fasting glucose, which should be initiated simultaneously at any HbA1c level to improve outcome in diabetes. A variety of both non-pharmacological and pharmacological therapies should be considered to target postmeal plasma glucose. Monitoring should occur as frequently as needed to guide therapy and SMBG should be considered. Subject to available therapies and resources, a 2-h postmeal plasma glucose target of ≤ 7.8 mmol/l (140 mg/dl) is considered both reasonable and achievable.

Comment

Since publication of the guideline, results from an interventional study of 644 outpatients with Type 2 diabetes demonstrated that the glucose spike (i.e. the difference between premeal glucose value and peak value of glycaemia during three different meals) was the most important predictor of CIMT progression compared with all examined glycaemic parameters, with peak value of glycaemia occurring 1.5 h after the start of the meal [50].

Competing interests

AC and SC have relationships with a wide range of organizations but development of the guideline, upon which this review was based, was supported by unrestricted educational grants from Amylin Pharmaceuticals, Eli Lilly and Company, LifeScan Inc., Merck & Co. Inc., Novo Nordisk A/S, Roche Diagnostics GmbH and Roche Pharmaceuticals.

References

1 International Diabetes Federation. Diabetes Atlas. 3rd edn. Brussels: International Diabetes Federation, 2006. Available at http://www.idf.org/media Last accessed 8 September 2008.
2 Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R et al. Management of hyperglycaemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29: 1963–1972.
3 Shiraiwa T, Kaneto H, Miyatsuka T, Kato K, Yamamoto K, Kawashima A et al. Postprandial hyperglycaemia is an important predictor of the incidence of diabetic microangiopathy in Japanese Type 2 diabetic patients. Biochem Biophys Res Commun 2003; 306: 339–345.
4 Levitan RB, Song Y, Ford ES, Liu S. Is non-diabetic hyperglycaemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med 2004; 164: 2147–2153.
5 Hanefeld M, Cagatay M, Petrowitsch T, Neurer D, Pitrima D, Rupp M. Acarbose reduces the risk for myocardial infarction in Type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2006; 25: 10–16.
6 Woerle HJ, Neumann C, Zschau S, Tenner S, Insigler A, Schirra J et al. Impact of fasting and postprandial glycaemia on overall glycemic control in Type 2 diabetes: importance of postprandial glycaemia to achieve target HbA1c levels. Diabetes Res Clin Pract 2007; 77: 280–285.
7 Hanefeld M, Koehler C, Schaper F, Fuerer K, Henkel E, Temelkova-Kurtschiev T. Postprandial plasma glucose is an independent risk factor for increased carotid intima-media thickness in non-diabetic individuals. Atherosclerosis 1999; 144: 229–235.
8 IDF Clinical Guidelines Task Force. Guideline for Management of Postmeal Glucose. Brussels: International Diabetes Federation, 2007.
9 WHO. Definition and Diagnosis of Diabetes Mellitus and Interim-Mediate Hyperglycemia. Report of a WHO/IDF Consultation. Geneva: World Health Organization, 2006; 1–46. Available at http://www.who.int Last accessed 8 September 2008.
10 Gerich JE. Pathogenesis and treatment of Type 2 (non-insulin-dependent) diabetes mellitus (NIDDM). Horm Metab Res 1996; 28: 404–412.
11 Pratley RE, Weyer C. The role of impaired early insulin secretion in the pathogenesis of Type 2 diabetes mellitus. Diabetologia 2001; 44: 929–945.
12 Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of Type 2 diabetes mellitus. J Clin Invest 1999; 104: 787–794.
13 Monnier L, Colette C, Dunseath GJ, Owens DR. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 2007; 30: 263–269.
14 Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycaemia of Type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care 2003; 26: 881–885.
15 Erlinger TP, Brancati FL. Postchallenge hyperglycemia in a national sample of US adults with Type 2 diabetes. Diabetes Care 2001; 24: 1734–1738.
16 Maia FF, Araujo LR. Efficacy of continuous glucose monitoring system (CGMS) to detect postprandial hyperglycaemia and unrecognized hyperglycaemia in Type 1 diabetic patients. Diabetes Res Clin Pract 2007; 75: 30–34.
17 UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet 1998; 352: 817–823.
18 Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA et al. Association of glycemia with macrovascular and microvascular complications of Type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000; 320: 405–412.
19 Cavalaro F, Petrelli A, Traversa M, Bonomo K, Fiora E, Conti M et al. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in Type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab 2006; 91: 813–819.
20 Nakagami T, Qiao Q, Tuomilehto J, Balkau B, Tajima N, Hu G et al. Screen-detected diabetes, hypertension and hypercholesterolemia as predictors of cardiovascular mortality in five populations of Asian origin: the DECODA study. Eur J Cardiovasc Prev Rehabil 2006; 13: 555–561.
21 DECODE Study Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-h diagnostic criteria. Arch Intern Med 2001; 161: 397–405.
22 Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmehel H et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 13-year follow-up. Diabetologia 1996; 39: 1577–1583.
23 Kawanou H, Morozuma T, Hirashima O, Hirai N, Miyao Y, Sakamoto T et al. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 1999; 34: 146–154.
35 Shimabukuro M, Higa N, Chinen I, Yamakawa K, Takasu N. Effects of postprandial hyperglycaemia and hyperglycaemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment. Diabetology 2004; 53: 701–710.

26 Scognamiglio R, Negrot C, De Kreutzenberg SV, Tiengo A, Avogaro A. Postprandial myocardial perfusion in healthy subjects and in Type 2 diabetic patients. Circulation 2005; 112: 179–184.

27 Stattin P, Bjor O, Ferrari P, Lukanova A, Lindahl B et al. Prospective study of hyperglycaemia and cancer risk. Diabetes Care 2007; 30: 561–567.

28 Abbatcola AM, Rizzo MR, Barbieri M, Grella R, Arciello A, Laiera MT et al. Postprandial plasma glucose excursions and cognitive functioning in aged Type 2 diabetics. Neurology 2006; 67: 235–240.

29 Esposito K, Giugliano D, Nappo F, Marfella R. Regression of carotid intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Circulation 2004; 110: 214–219.

30 Chaisson JL, Josse RG, Comin R, Hanefeld M, Karasuk A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. J Am Med Assoc 2003; 290: 486–494.

31 Hanefeld M, Chaisson JL, Kohler C, Henkel H, Schaper F, Temeleva-Kurktschiev T. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke 2004; 35: 1073–1078.

32 Reisswenger PJ, Howell SK, O’Dell RM, Wood ME, Touchette AD, Sewergold RS. α-Dicarbonyls increase in the postprandial period and reflect the degree of hyperglycaemia. Diabetes Care 2004; 27: 726–732.

33 Ceriello A. The post-prandial state and cardiovascular disease: relevance to diabetes mellitus. Diabetes Metab Rev 2000; 16: 325–332.

34 Ceriello A, Quagliaro L, Catone B, Pascon R, Piazzola M, Bais B et al. Role of hyperglycaemia in nitrotyrosine postprandial generation. Diabetes Care 2002; 25: 1439–1443.

35 Shimabukuro M, Higa N, Chinen I, Yamakawa K, Takasu N. Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in Type 2 diabetic patients: a randomized crossover study. J Clin Endocrinol Metab 2006; 91: 837–842.

36 Holman RR, Thorne KL, Farmer AJ, Davies MJ, Kreman JF, Paul S et al. 4T Study Group. Addition of biaxin, prandial, or basal insulin to oral therapy in Type 2 diabetes. N Engl J Med 2007; 357: 1716–1730.

37 American Diabetes Association. Clinical practice recommendations 2007: diagnosis and classification of diabetes mellitus. Diabetes Care 2007; 30: S42–S47.

38 Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2003 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2003; 27: S21.

39 IDF Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes. Brussels: International Diabetes Federation, 2005.

40 Wolfever TM, Yang M, Zeng XY, Atkinson F, Brand-Miller JC. Food glycemic index, as given in glycemic index tables, is a significant determinant of glycemic responses elicited by composite breakfast meals. Am J Clin Nutr 2006; 83: 1306–1312.

41 McMillan-Price J, Perrotta P, Atkinson F, O’Neill K, Samman S, Steinbeck K et al. Comparison of 4 diets of varying glycemic load on weight loss and cardiovascular risk reduction in overweight and obese young adults: a randomized controlled trial. Arch Intern Med 2006; 166: 1466–1475.

42 Brand-Miller JC, Perrotta P, Colagiuri S. Meta-analysis of low-glycemic index diets in the management of diabetes: response to Franz. Diabetes Care 2003; 26: 336–3364; author reply 3364–3365.

43 Opperman AM, Venter CS, Oosthuizen W, Thompson RL, Vorster HH. Meta-analysis of the health effects of using the glycaemic index in meal-planning. Br J Nutr 2004; 92: 367–381.

44 Ceriello A, Piconi L, Quagliaro L, Wang Y, Schnabel CA, Ruggles JA et al. Effects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with Type 1 diabetes. Diabetes Care 2005; 28: 63–67.

45 Ahren B, Schmitz O. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of Type 2 diabetes. Horm Metab Res 2004; 36: 867–876.

46 American Association of Clinical Endocrinologists. Medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007; 13: 1–68.

47 Polonsky KS, Given BD, Van Cauter E. Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest 1988; 81: 442–448.

48 Farmer A, Wade A, Goyder E, Yudkin P, French D, Craven A et al. Effect of self-monitoring of blood glucose in the management of patients with non-insulin-treated diabetes: open parallel group randomised trial. Br Med J 2007; 335: 132.

49 Jansen JP. Self-monitoring of glucose in Type 2 diabetes mellitus: a Bayesian meta-analysis of direct and indirect comparisons. Curr Med Res Opin 2006; 22: 671–681.

50 Esposito K, Ciotola M, Carlos D, Schisano B, Sardelli L, Di Tommaso D et al. Post-meal glucose peaks at home associate with carotid intima-media thickness in Type 2 diabetes. J Clin Endocrinol Metab 2008; 93: 1345–1350.